Nilestriol

Nilestriol
Clinical data
Trade names	Wei Ni An
Other names	Nylestriol; LY-49825; Ethinylestriol cyclopentyl ether; EE3CPE; 17α-Ethynylestriol 3-cyclopentyl ether
Routes of; administration	By mouth
Drug class	Estrogen; Estrogen ether
Identifiers
	IUPAC name (8R,9S,13S,14S,16R,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-16,17-diol;
CAS Number	39791-20-3;
PubChem CID	38346;
ChemSpider	35146;
UNII	7JA3B3IALU;
KEGG	D05212;
ChEMBL	ChEMBL2104468;
CompTox Dashboard (EPA)	DTXSID601043308 ;
Chemical and physical data
Formula	C25H32O3
Molar mass	380.528 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@]2(C#C)O)O)CCC4=C3C=CC(=C4)OC5CCCC5;
	InChI InChI=1S/C25H32O3/c1-3-25(27)23(26)15-22-21-10-8-16-14-18(28-17-6-4-5-7-17)9-11-19(16)20(21)12-13-24(22,25)2/h1,9,11,14,17,20-23,26-27H,4-8,10,12-13,15H2,2H3/t20-,21-,22+,23-,24+,25+/m1/s1; Key:CHZJRGNDJLJLAW-RIQJQHKOSA-N;

Nilestriol (INNTooltip International Nonproprietary Name) (brand name Wei Ni An; developmental code name LY-49825), also known as nylestriol (USANTooltip United States Adopted Name, BANTooltip British Approved Name), is a synthetic estrogen which was patented in 1971^[1] and is marketed in China.^[2]^[3] It is the 3-cyclopentyl ether of ethinylestriol, and is also known as ethinylestriol cyclopentyl ether (EE3CPE).^[4] Nilestriol is a prodrug of ethinylestriol, and is a more potent estrogen in comparison.^[4] It is described as a slowly-metabolized, long-acting estrogen and derivative of estriol.^[5]^[6] Nilestriol was assessed in combination with levonorgestrel for the potential treatment of postmenopausal osteoporosis, but this formulation ultimately was not marketed.^[7]

References

^ Official Gazette of the United States Patent and Trademark Office: Patents. U.S. Department of Commerce, Patent and Trademark Office. 1975. p. 1677.
^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 891–. ISBN 978-1-4757-2085-3.
^ "Nilestriol". Drugs.com.
^ ^a ^b McGuire W (14 December 2013). Experimental Biology. Springer Science & Business Media. pp. 161–. ISBN 978-1-4757-4673-0.
^ Schoenberg DR (1977). Biochemical Properties of the Cytoplasmic Estrogen Receptors from Immature Rat and Mature Rabbit Uteri (Ph.D. thesis). University of Wisconsin. p. A-17.
^ "Section 10: Obstetrics and gynecology". Excerpta Medica. 1978.
^ Aronson JK (21 February 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. pp. 173–. ISBN 978-0-08-093292-7.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

This article about a steroid is a stub. You can help Wikipedia by expanding it.

[1] Official Gazette of the United States Patent and Trademark Office: Patents. U.S. Department of Commerce, Patent and Trademark Office. 1975. p. 1677.

[Elks2014-2] Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 891–. ISBN 978-1-4757-2085-3.

[Drugs.com-3] "Nilestriol". Drugs.com.

[McGuire2013-4] McGuire W (14 December 2013). Experimental Biology. Springer Science & Business Media. pp. 161–. ISBN 978-1-4757-4673-0.

[Schoenberg1977-5] Schoenberg DR (1977). Biochemical Properties of the Cytoplasmic Estrogen Receptors from Immature Rat and Mature Rabbit Uteri (Ph.D. thesis). University of Wisconsin. p. A-17.

[ExcerptaMedica1978-6] "Section 10: Obstetrics and gynecology". Excerpta Medica. 1978.

[Aronson2009-7] Aronson JK (21 February 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. pp. 173–. ISBN 978-0-08-093292-7.

[1]

Nilestriol

See also

References